Searchable abstracts of presentations at key conferences in endocrinology

ea0022p41 | Adrenal | ECE2010

Response of human adrenocortical carcinoma to mitotane treatment in vitro

van Koetssveld Peter , van Rutte Karlijn , Waaijers Marlijn , de Krijger Ronald , Lamberts Steven , Feelders Richard , de Herder Wouter , Hofland Leo

Introduction: Adrenocortical carcinoma (ACC) is a rare, but highly malignant endocrine tumor. Surgery is the primary choice of treatment. In case of inoperable disease or tumor recurrence, therapy with the adrenolytic drug mitotane is usually applied. Plasma mitotane concentrations of >14 mg/l (50 μM) seem required for an effect on tumor mass. Despite its clinical use, the effects of mitotane on cell proliferation and hormone production have been poorly investigated <...

ea0022p22 | Adrenal | ECE2010

Comparison of the in vitro effects of ketoconazole and fluconazole on human primary adrenocortical cultures and on the adrenocortical carcinoma cell line HAC15

van der Pas Rob , Hofland Leo , Waaijers Marlijn , de Jong Frank , Uitterlinden Piet , de Herder Wouter , van Koetsveld Peter , Feelders Richard

Introduction: Ketoconazole is an antifungal agent that, in a high dose, suppresses adrenocortical steroidogenesis by inhibition of cytochrome P-450 dependent enzymes. Currently, ketoconazole is used to decrease cortisol production in patients with Cushing’s syndrome. However, ketoconazole often causes gastrointestinal side effects and hepatotoxicity. Fluconazole may also inhibit steroidogenesis and has the advantage over ketoconazole that it has less side effects. Therefo...